Purdue Develops New Strategy for Drug Discovery

Posted: Updated:
Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials. Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials.

Research scientists often confront the “valley of death”—the gaping hole that exists between laboratory discoveries and their transformation into new medical treatments and products. And the most lethal factor for most researchers is money. However, Purdue University is blazing an unusual trail to help make ends meet in translational research. Rather than rely on traditional sources, the university has formed a not-for-profit startup to take discoveries from the lab up to Phase 1 human clinical trials.

“We develop a lot of drugs [at Purdue]; there aren’t many academic institutions or cancer centers [in our position]—with 14 of their drugs that are synthesized at their own institution in human clinical trials,” says Purdue Center for Cancer Research Robert Wallace Miller Director Dr. Tim Ratliff. “It’s a real strength here, and we want to improve and speed the process.”

Translating basic research into life-changing treatments is one initiative of Purdue Moves, a program that involves 10 university initiatives designed to enhance research, education and the school’s global impact.

Purdue’s Center for Cancer Research is one of only seven basic science research centers in the country designated by the National Cancer Institute. While Ratliff describes the center as a very efficient entity that can “move things forward in a rapid manner,” the process is still slower than scientists like.

Researchers typically rely on external funding from government sources to help them uncover a discovery, but beyond that, the money often dries up.

“[Government sources] don’t fund drugs from the discovery through all these routine processes you have to go through to get that drug ready to go into clinical trials,” says Ratliff. “You have to take these drugs and develop them, so that we understand the toxicities associated with them, their distribution in the body and other fundamental things before we get into the clinic.”

This is when most scientists encounter the “valley of death,” but Purdue believes it can finance the very expensive process with its newly formed Boilermaker Health Innovations, a not-for-profit startup that represents a unique way to fund the gap. Boilermaker Health believes it will be much speedier than the traditional route of forming for-profit companies that aim to attract investments to reach human clinical trials.

Once Boilermaker Health has funded a scientist through early research, Ratliff says it will spin-off a for-profit company to develop the compound and take it through U.S. Food and Drug Administration approval or sell the drug to a large pharmaceutical company.

“As we develop these drugs from very early stages, we envision those drugs will gain value,” says Ratliff. “While we’re a not-for-profit company, that value will create a fund in Boilermaker Health that will allow us, over time, to become independent and support our cancer research and drug discovery very efficiently through the use of those funds.”

Ratliff acknowledges the unconventional model begs the question of how Boilermaker Health will get its first infusion of cash; he says it will rely on Purdue donors, federal funding agencies and private foundations. The Purdue Research Foundation is also matching each donation, up to a total of $1.3 million.

Additionally, Boilermaker Health is considering an alumni crowdfunding effort. The startup has already received a commitment of $175,000 and is “pushing hard” to collect more donations.

“Earning the match would give us $2.6 million, and that would be sufficient to move our first compound through pre-clinical analyses,” says Ratliff. “Once Boilermaker Health gets the drug through the proof of principle clinical trial, that will enable us to sell the product at a higher value, and that higher value will bring revenue back in. The money that we get back, we re-invest into drug discovery, amplifying our ability to move drugs through the valley of death.”

An external advisory committee is currently evaluating compounds in the Purdue pipeline to select the first for Boilermaker Health to “shepherd.” Leaders are hopeful the university’s unique strengths in drug discovery will also pave an unconventional path to patients.

Ratliff says there’s one question he gets the most about Boilermaker Health Innovations.
Ratliff says an external advisory committee will select the first compound that Boilermaker Health Innovations will “shepherd.”
  • Perspectives

    • Creating a Customer-Centric Marketing Strategy For Your Healthcare Business

      Obtaining and retaining customers is critical, especially in highly competitive markets like the healthcare industry. But, differentiating your organization with an exceptional customer experience can help you stay ahead in the $3.4 trillion industry. According to McKinsey, 70 percent of buying experiences are based on how the customer feels they’re being treated. Now more than ever the customer’s satisfaction needs to be at the top of focus for companies looking to...

    More

Events



  • Most Popular Stories

    • Infosys Picks Indy For Training Center, 1K Additional Jobs

      Inside INdiana Business has learned that India-based tech giant Infosys (NYSE: INFY) will house a USA Training Center at the old Indianapolis International Airport site. The plans involve 1,000 new jobs, on top of the company's previous commitment of 2,000 new jobs as part of its downtown technology and innovation hub. Vice President Mike Pence will join Governor Eric Holcomb and others for the official announcement Thursday in Indianapolis.

    • Manufacturer Adding Production in Daviess County

      Florida-based ISOFlex Packaging will Tuesday celebrate the opening of a third production line at its facility in Daviess County. The company, which produces specialty plastic films and bags, will add a small number of jobs as a result. The company has invested more than $4 million into the new production line. The facility originally opened in 2014 following a $25 million investment by Alliance Barrier Films, which was acquired by ISOFlex in January.

    • 'Supercar' Assembly Operation Planned For Purdue

      The England-based manufacturer of a car billed as the fastest street-legal vehicle on the road has selected the Discovery Park District at Purdue University for a showroom and assembly facility. Keating Supercars LLC will produce its first model to be sold in the U.S., the Viperia Berus coupe, which is capable of reaching speeds greater than 230 miles-per-hour. The company is slated to cut the ribbon on the showroom late next month and eventually ramp up production at Purdue to...

    • (Service area map provided by Vectren.)

      What Does Vectren Merger Mean?

      A utility industry observer says he does not think the planned $6 billion merger of Evansville-based Vectren Corp. (NYSE: VVC) and CenterPoint Energy Inc. (NYSE: CNP) will have a major impact in Indiana. Doug Gotham, who serves as director of the State Utility Forecasting Group at Purdue University, also says he is not aware of any recent mergers that have been shut down by Federal Energy Regulatory Commission, a key hurdle that remains to be cleared. CenterPoint says plans...

    • IN3, formerly API, involves major defense, govermental, economic development and academic stakeholders from throughout the state.

      New Name, First Contract For Defense Tech-Focused Institute

      Indiana Innovation Institute, formerly known as the Applied Research Institute, is kicking off a rebranding with the announcement of its first contract. The $2.3 million trusted microelectronics collaboration with Purdue University also includes researchers and personnel from the Crane Naval Surface Warfare Center, Indiana University and the University of Notre Dame. The work involves rapid development of counterfeit-resistant technology that is immune to global attacks.